JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roth, L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roth, L. W.
Journal of Pharmacology And Experimental Therapeutics, Vol. 110, Issue 2, 157-165, 1954
Copyright © 1954 by American Society for Pharmacology and Experimental Therapeutics


BLOCKING EFFECTS OF A SERIES OF SUBSTITUTED PIPERAZINES

L. W. Roth 1

1 Department of Pharmacology, Abbott Laboratories, North Chicago, Illinois

In a series of substituted piperazines, phenyl methyl piperazine (A1390) was found to have potent adrenergic blocking activity in animals. It blocks and reverses the pressor effects of epinephrine. It blocks, but does not reverse, the pressor effects of nor-epinephrine, ephedrine, desoxyephedrine and hydroxyamphetamine, but does not block naphthyl-methyl-imidazoline.

A1390 blocks the pressor response to anoxia, tilting, and carotid sinus occlusion. It also blocks the nictitating membrane response to superior cervical nerve stimulation.

A1390 does not prevent epinephrine tachycardia nor reduce epinephrine toxicity in mice. It has little atropine-like action, and is only weakly antihistaminic. It does not have a direct vasodilator action in the perfused rabbit ear or heart. The local anesthetic potency of this compound is comparable to that of procaine. Its antihypertensive action in rats has a duration much longer than the adrenolytic activity. A small rise in threshold for vagal inhibition of the heart occurred only after large doses of A1390.

Acute and chronic toxicity data indicate that its therapeutic ratio is relatively favorable.

Examination of the properties of congeners did not reveal consistent or definitive structure-activity relationships.

Submitted on August 22, 1953







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1954 by the American Society for Pharmacology and Experimental Therapeutics.